mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis

New England Journal of Medicine

Volumn 326, Issue 4, 1992, Pages 213-220

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; FOSCARNET; FOSCARNET SODIUM; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LEVKINE; PENTAMIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AEROSOL; AIDS RELATED COMPLEX; ARTICLE; CATHETER INFECTION; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; HELPER CELL; HEMOGLOBIN DETERMINATION; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MORTALITY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINITIS; RISK; SURVIVAL RATE; THROMBOCYTE COUNT; VISUAL IMPAIRMENT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; COMPARATIVE STUDY; CYTOMEGALOVIRUS INFECTIONS; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; FOSCARNET; GANCICLOVIR; HUMAN; LEUKOCYTE COUNT; PHOSPHONOACETIC ACID; RANDOM ALLOCATION; RETINITIS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; ZIDOVUDINE;

EID: 11944275015     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199201233260401     Document Type: Article

References (47)

1. Holland G.N., Pepose J.S., Pettit T.H., Gottlieb M.S., Yee R.D., Foos R.Y. Acquired immune deficiency syndrome: ocular manifestations. Ophthalmology 1983; 90:859-73
2. Rosenberg P.R., Uliss A.E., Friedland G.H., Harris C.A., Small C.B., Klein R.S. Acquired immunodeficiency syndrome: ophthalmic manifestations in ambulatory patients. Ophthalmology 1983; 90:874-8
3. Palestine A.G., Rodrigues M.M., Macher A.M., et al. Ophthalmic involvement in acquired immunodeficiency syndrome. Ophthalmology 1984; 91:1092-9
4. Freeman W.R., Lerner C.W., Mines J.A., et al. A prospective study of the ophthalmologic findings in the acquired immune deficiency syndrome. Am J Ophthalmol 1984; 97:133-42
5. Newsome D.A., Green W.R., Miller E.D., et al. Microvascular aspects of acquired immune deficiency syndrome retinopathy. Am J Ophthalmol 1984; 98:590-601
6. Pepose J.S., Holland G.N., Nestor M.S., Cochran A.J., Foos R.Y. Acquired immune deficiency syndrome: pathogenic mechanisms of ocular disease. Ophthalmology 1985; 92:472-84
7. Schuman J.S., Orellana J., Friedman A.H., Teich S.A. Acquired immunodeficiency syndrome (AIDS). Surv Ophthalmol 1987; 31:384-410
8. Jacobson M.A., O#x0027;Donnell J.J., Porteous D., Brodie H.R., Feigal D., Mills J. Retinal and gastrointestinal disease due to cytomegalovirus in patients with the acquired immune deficiency syndrome: prevalence, natural history, and response to ganciclovir therapy. Q J Med 1988; 67:473-86
9. Jabs D.A., Enger C., Bartlett J.G. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol 1989; 107:75-80
10. Jabs D.A., Green W.R., Fox R., Polk B.F., Bartlett J.G. Ocular manifestations of acquired immune deficiency syndrome. Ophthalmology 1989; 96:1092-9
11. Palestine A.G., Stevens G. Jr., Lane H.C., et al. Treatment of cytomegalovirus retinitis with dihydroxy propoxymethyl guanine. Am J Ophthalmol 1986; 101:95-101
12. Collaborative DHPG Treatment Study Group. Treatment of serious cytomegalovirus infections with 9-(l,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies. N Engl J Med 1986; 314:801-5
13. Holland G.N., Sidikaro Y., Kreiger A.E., et al. Treatment of cytomegalovirus retinopathy with ganciclovir. Ophthalmology 1987; 94:815-23
14. Jabs D.A., Newman C., De Bustros S., Polk B.F. Treatment of cytomegalovirus retinitis with ganciclovir. Ophthalmology 1987; 94:824-30
15. Laskin O.L., Cederberg D.M., Mills J., et al. Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus. Am J Med 1987; 83:201-7
16. Henderly D.E., Freeman W.R., Causey D.M., Rao N.A. Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology 1987; 94:425-34
17. Orellana J., Teich S.A., Friedman A.H., Lerebours F., Winterkorn J., Mildvan D. Combined short- and long-term therapy for the treatment of cytomegalovirus retinitis using ganciclovir (BW B759U). Ophthalmology 1987; 94:831-8
18. Holland G.N., Buhles W.C., Mastre B., Kaplan H.J. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy: use of a standardized system for the assessment of disease outcome. Arch Ophthalmol 1989; 107:1759-66
19. Walmsley S.L., Chew E., Read S.E., et al. Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (Foscarnet). J Infect Dis 1988; 157:569-72
20. LeHoang P., Girard B., Robinet M., et al. Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 1989; 96:865-73
21. Jacobson M.A., O#x0027;Donnell J.J., Mills J. Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Antimicrob Agents Chemother 1989; 33:736-41
22. Palestine A.G., Polis M.A., De Smet M.D., et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1991; 115:665-73
23. Gross J.G., Bozzette S.A., Mathews W.C., et al. Longitudinal study of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 1990; 97:681-6
24. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Studies of Ocular Complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. 1. Rationale, design, and methods. Controlled Clin Trials (in press)
25. Hochster H., Dieterich D., Bozzette S., et al. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS: an AIDS Clinical Trials Group Study. Ann Intern Med 1990; 113:111-7
26. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987; 36:Suppl 1S:1S-15S
27. Collier AC, Bozzette S., Coombs R.W., et al. A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med 1990; 323:1015-21
28. Karnofsky D.A., Abelmann W.H., Craver L.F., Burchenal J.H. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948; 1: 634-56
29. Giorgi J.V. Lymphocyte subset measurements: significance in clinical medicine. In: Rose NR, Friedman H, Fahey JL, eds. Manual of clinical laboratory immunology. 3rd ed. Washington, D.C.: American Society for Microbiology, 1986: 236-46
30. Jackson A.L., Warner N.L. Preparation, staining, and analysis by flow cytometry of peripheral blood leukocytes. In: Rose NR, Friedman H, Fahey JL, eds. Manual of clinical laboratory immunology. 3rd ed. Washington, D.C.: American Society for Microbiology, 1986: 226-35
31. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41
32. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81
33. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50:163-70
34. Peto R., Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc [A] 1972; 135:185-206
35. SAS Institute, Inc. SAS/STAT software: the PHREG procedure. Cary, N.C.: SAS Institute, 1991
36. Cox D.R. Regression models and life-tables. J R Stat Soc [B] 1972; 34:187-220
37. Lipsitz S.R., Harrington D.P. Analyzing correlated binary data using SAS. Comput Biomed Res 1990; 23:268-82
38. McCullagh P., Nelder J.A. Generalized linear models. 2nd ed. London: Chapman & Hall, 1989
39. Royall R.M. Model robust confidence intervals using maximum likelihood estimators. Int Stat Rev 1986; 54:221-6
40. Zeger S.L., Liang K.Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42:121-30
41. Yusuf S., Wittes J., Probstfield J., Tyroler H.A. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991; 266:93-8
42. Canner P.L. Monitoring clinical trial data for evidence of adverse or beneficial treatment effects. In: Boissel JP, Klimt CR, eds. Essais controles multi-centres: principes et problemes. Vol. 76. Paris: Institut National de la Santé et de la Recherche Medicale (INSERM), 1977: 131-49
43. Holland G.N., Sison R.F., Jatulis D.E., Haslop M.G., Sakamoto M.J., Wheeler N.C. Survival of patients with the acquired immune deficiency syndrome after development of cytomegalovirus retinopathy. Ophthalmology 1990; 97:204-11
44. Harb G.E., Bacchetti P., Jacobson M.A. Survival of patients with AIDS and cytomegalovirus disease treated with ganciclovir or foscarnet. AIDS 1991; 5: 959-65
45. Eriksson B.F.H., Schinazi R.F. Combinations of 3#x0027;-azido-3#x0027;-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro. Antimicrob Agents Chemother 1989; 33:663-9
46. Kong X.-B., Zhu Q.-Y., Ruprecht R.M., et al. Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3#x0027;-azido-3#x0027;-deoxythymidine, phosphonoformate, and 2#x0027;,3#x0027;-dideoxythymidine. Antimicrob Agents Chemother 1991; 35:2003-11
47. Jacobson M.A., van der Horst C., Causey D.M., Dehlinger M., Hafner R., Mills J. In vivo additive antiretroviral effect of combined zidovudine and foscarnet therapy for human immunodeficiency virus infection (AGTG Protocol 053). J Infect Dis 1991; 163:1219-22